PT
Poplar Therapeutics
Developing a new class of anti-IgE therapy for multiple atopic conditions.
About
Poplar Therapeutics is a biotechnology company focused on developing novel therapies for atopic conditions. Their lead program, PHB-050, is a new class of anti-IgE therapy designed to address a range of allergic diseases.
Technology stack
detected 2026-06-17Est. monthly stack spend~$150/mo
CDN
Cloudflare
Email
Microsoft 365
Stack
jQuery
WordPress
Analytics
Google Analytics 4
SEO
Yoast SEO
Comments
No comments yet. Be the first to share your take.
Frequently asked
What does Poplar Therapeutics do?
Poplar Therapeutics is a biotechnology company focused on developing novel therapies for atopic conditions. Their lead program, PHB-050, is a new class of anti-IgE therapy designed to address a range of allergic diseases.
How much funding has Poplar Therapeutics raised?
Poplar Therapeutics has raised a total of $50M in funding. The most recent round on record is Series A.
Where is Poplar Therapeutics headquartered?
Poplar Therapeutics is headquartered in Boston, Massachusetts, USA.
When was Poplar Therapeutics founded?
Poplar Therapeutics was founded in 2021.
What industry does Poplar Therapeutics operate in?
Poplar Therapeutics operates in Biotechnology, Pharmaceuticals, HealthTech.
How many employees does Poplar Therapeutics have?
Poplar Therapeutics has approximately 8 people on record.